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Abstract
Background: Gliomas are the most common primary brain tumors in adults and invariably carry a poor prognosis.
Recent clinical studies have demonstrated the safety and compelling survival benefit when tumor treating fields
(TTFields) are added to temozolomide for patients with newly diagnosed glioblastoma. TTFields are low-intensity,
intermediate frequency (200 kHz) alternating electric fields, delivered directly to a patient’s brain through the local
application of non-invasive transducer arrays. Experimental simulations have demonstrated that TTFields distribute
in a non-uniform manner within the brain. To ensure patients receive the maximal therapeutic level of TTFields at
the site of their tumor, tumor burden is mapped and an optimal array layout is personalized using the NovoTAL
software. The NovoTAL software utilizes magnetic resonance imaging (MRI) measurements for head size and tumor
location obtained from axial and coronal T1 postcontrast sequences to determine the optimal paired transducer
array configuration that will deliver the maximal field intensity at the site of the tumor. In clinical practice,
physicians planning treatment with TTFields may determine that disease activity is more accurately represented in
noncontrast-enhancing sequences. Here we present and discuss a series of 8 cases where a treating physician has
utilized non-contrast enhancement and advanced imaging to inform TTFields treatment planning based on a
clinical evaluation of where a patient is believed to have active tumor. This case series is, to our knowledge, the first
report of this kind in the literature.
Case presentations: All patients presented with gliomas (grades 2–4) and ranged in age from 49 to 65 years; 5
were male and 3, female. Each patient had previously received standard therapy including surgery, radiation
therapy and/or chemotherapy prior to initiation of TTFields. The majority had progressed on prior therapy. A
standard pre- and postcontrast MRI scan was acquired and used for TTFields treatment planning.
Conclusion: This paper details important approaches for integrating clinical considerations, nonmeasurable disease
and advanced imaging into the treatment planning workflow for TTFields. As TTFields become integrated into
standard care pathways for glioblastoma, this case series demonstrates that treatment planning beyond the extent
of contrast enhancement is clinically feasible and should be prospectively compared to standard treatment
planning in a clinical trial setting, in order to determine the impact on patient outcomes.
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Background
Despite significant advances in the detection, imaging
and treatment planning for brain tumors, overall
prognosis remains bleak and there remain no curative
treatments for high-grade gliomas. There is a signifi-
cant unmet need for life-extending therapies that can
preserve a patient’s quality of life, given that patients
with glioblastoma multiforme (GBM) have a median
survival of approximately 16 months, even with ag-
gressive therapy [1–3]. Tumor treating fields
(TTFields) are low-intensity (1–3 V/cm), intermediate
frequency (200 kHz), alternating electric fields ap-
proved for the management of patients with both
newly diagnosed and recurrent GBM [4, 5]. Optune™
(NovoTTF-100A System) is a Food and Drug Admin-
istration (FDA) approved device that locally delivers
TTFields to a patient’s head through paired trans-
ducer arrays, which are worn continuously on the
scalp. At therapeutic field intensities, TTFields will se-
lectively target dividing cancer cells, sparing quiescent
cells [6, 7].
TTFields fall within the spectrum of nonionizing radi-
ation and differ in their biologic behavior compared with
radiation therapy (RT). In general, high energy gamma
radiation has a frequency in the order of exahertz (1020),
with a wavelength of picometers (10−19), less than the
diameter of an atom [8]. As the frequency of TTFields is
much lower at 200 kHz, and the wavelength much lon-
ger (~1 mile), TTFields cannot be precisely focused and
delivered to discrete regions of the brain in the same
focal manner as RT [9, 10]. Treatment can, however, be
optimized to ensure that field intensity is maximal at the
site of a tumor [11–13], a process which involves plan-
ning with the NovoTAL System software.
Conventional treatment planning for TTFields, which
is a requisite for all patients commencing therapy, is per-
formed using axial and coronal T1-post contrast MRI
measurements and the NovoTAL™ system. The methods
for performing treatment planning have been described
previously [11], but in brief, consist of obtaining 20 mea-
surements delineated on T1 postcontrast sequences
from the patient’s most recent MRI scan. Coordinate di-
mensions are obtained for head size using T1 postcon-
trast sequences, on a slice at the superior level of the
orbit. A box is drawn at the level of the scalp. Head size
measurements are obtained for the maximal anterior-
posterior (A-P), right to left lateral (R-L) and right to
anatomic midline distances and are recorded on a plan-
ning worksheet. The size of the cerebrum is estimated
from a coronal T1 postcontrast slice at the level of the
external auditory canal, commencing from a reference
frame drawn at the level of the scalp. The horizontal
margin of this box extends inferiorly to the lower mar-
gins of temporal lobe. Superior-to-inferior, R-L and right
to anatomic midline measurements on coronal views
are obtained and recorded on the worksheet. In con-
ventional treatment planning, tumor location coordi-
nates from similar reference frames are obtained in
both axial and coronal views, selecting the T1 post-
contrast slices that contain the maximal extent of en-
hancing disease. Reference frames are drawn around
the head at the level of the scalp, and the same 3 di-
mensions as described for head size are obtained in
the axial view and coronal views. In addition in the
axial sequence, distances to the edge of tumor are ob-
tained from the right frame to near and far tumor
margins, and from the anterior frame to the near and
far tumor margins. In the coronal slice, tumor coordi-
nates are obtained from the right frame to the near
and far tumor margins, and from the top of the
frame to the near and far tumor margins. All mea-
surements are rounded to the nearest mm and re-
corded on the planning worksheet. Once complete,
the measurements are entered into the NovoTAL
software in order to generate a personalized trans-
ducer array layout map. The layout map is used to
direct TTFields treatment.
As mentioned, conventional treatment mapping is
typically targeted to the margins of a lesion as repre-
sented by an area of maximal contrast enhancement
viewed on axial and coronal MRI frames. However,
the contrast enhancement defines areas where the
blood–brain barrier is disrupted and mapping treat-
ment exclusively on postcontrast imaging does not
take into account nonmeasurable disease that is none-
nhancing and which may extend beyond the margins
of these highly infiltrative tumors. Therefore, in clin-
ical practice, constraining planning to the extent of
enhancing disease may not target all the clinically
relevant disease foci that can be determined with
other sequences such T2 FLAIR and DWI. Response
assessment in high grade gliomas is complex due to
tumor heterogeneity and the impact of prior therapies
on imaging. The Response Assessment in Neuro-
Oncology (RANO) are the current criteria used by
the neurooncology community in the clinical practice
and clinical trial settings, and these criteria have in-
corporated the identification of nonenhancing, infiltra-
tive tumor into response assessment to address the
limitations of using only contrast enhancing images
[14]. Consequently, it is appropriate for treating phy-
sicians to incorporate their knowledge of both enhan-
cing and nonenhancing disease into the treatment
planning for patients receiving TTFields. Given the
paucity of literature on treatment planning ap-
proaches with TTFields, we report a series of cases
demonstrating feasibility of using alternate MRI se-
quences when planning therapy with TTFields.
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Case presentation
Practice scenario 1: selective use of contrast-
enhancement to map to areas likely to represent active
disease
Case A
A 54-year-old man with a longstanding history of sei-
zures developed new left-sided weakness and was found
to have a brain tumor. He underwent a gross total resec-
tion and pathology confirmed a diagnosis of GBM with
both astrocytic and oligodendroglial features, MGMT
unmethylated, IDH1 wild-type and no loss of 1p19q. He
was treated with conventional chemo-RT and opted to
add TTFields to his maintenance temozolomide. His
postradiation MRI showed no clear contrast enhance-
ment and only minor fluid-attenuated inversion recovery
(FLAIR) changes. MRI measurements for NovoTAL
treatment planning were thus determined using the pre-
operative scans (Fig. 1a-c).
Case B
A 49-year-old man developed left arm weakness. Im-
aging revealed a ring-enhancing nodule in the poster-
ior right frontal lobe. He underwent a gross total
resection with pathology confirming a GBM, MGMT
unmethylated. He was treated with conventional
chemo-RT, followed by 1 cycle of maintenance temo-
zolomide. The patient experienced disease progression
and was started on bevacizumab, with continuation of
temozolomide. After completing 6 cycles of temozolo-
mide, he had a further progression and underwent a
repeat tumor resection, with placement of Gliadel
wafers. Following the surgery, he received bevacizumab in
combination with dose-intense (daily) temozolomide for
2 months. Subsequently, the patient developed new symp-
toms of worsening left-sided weakness. Imaging per-
formed at that time demonstrated three areas of abnormal
enhancement, including the resection cavity with Gliadel
wafers, an enhancing area in the medial right frontal lobe
suggestive of a subdural collection, and a new enhancing
mass in the deep right hemisphere (Fig. 2). NovoTAL
mapping was performed utilizing measurements of the
deep tumor, and TTFields therapy was initiated.
Clinical commentary
Conventional NovoTAL treatment planning is focused
on determining coordinates from a fixed frame to the
proximal and distal borders of contrast enhancement
viewed on axial and coronal MRI images. In patients
newly diagnosed with glioblastoma, TTFields are
commenced in combination with maintenance temo-
zolomide and treatment is typically planned using a
4-week post-RT MRI. In Case A, the post-RT MRI
did not reveal any abnormal contrast enhancement.
Therefore, the treating physician utilized the pre-
operative postcontrast scan to perform NovoTAL
mapping and generate an array layout map to
maximize electrical field intensity in the region of
preoperatively visible tumor. In Case B, three areas of
abnormal enhancement were visualized on the
TTFields planning MRI. Based on the patient’s treat-
ment history and new clinical symptoms, the treating
physician determined that the new nodule in the deep
right hemisphere represented the area of active dis-
ease. The enhancement in the resection cavity with
Fig. 1 a, b & c: Figure a demonstrates post-operative loss of contrast-enhancing disease in a glioblastoma patient post gross total resection. b
and c show pre-operative axial and coronal views of the tumor. NovoTAL mapping was performed using pre-operative T1 postcontrast sequences
in a standard manner. Head size measurements were determined on axial and coronal views (not shown). In figure b, axial tumor location was
determined measuring from a reference frame drawn at the level of the scalp. Axial tumor locations measurements are shown A-P (2), R-L (3), R-
midline (5), right to near tumor margin (6), right to far tumor margin (4), front to near tumor margin (8), front to far tumor margin (9). Figure c
shows tumor location measurements obtained in coronal view. All measurements originate from a reference frame drawn at the level of scalp,
extending inferiorly to the lower margins of temporal lobe. The coronal tumor location measurements consist of a superior to inferior measurement
(2), R-L (3), right to midline (5), right to close (6) and right to far (7) tumor margins, and superior to close (8) and superior to far (9) tumor
margin measures
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Gliadel wafers and the subdural collection were
deemed to represent treatment effect without active
disease. Therefore, NovoTAL mapping was performed
on the region of contrast enhancement believed to be
most reflective of active disease. In both cases, the
treating physician made a determination that T1-
postcontrast enhancement either underestimated or
overestimated extent of disease and performed treat-
ment mapping based on where they understood most
active disease was present.
Practice scenario 2: mapping to active disease
represented by T2/FLAIR sequences
Case C
A 65-year-old man initially presented with word pro-
cessing difficulties. MRI of the brain revealed a heteroge-
neously enhancing left temporo-occipital mass. He
underwent an awake craniotomy with subtotal resection.
Pathology was consistent with GBM, IDH1 wild-type,
MGMT unmethylated. He was treated with conventional
chemo-RT. His postradiation MRI showed disease pro-
gression and bevacizumab was initiated, resulting in a
radiographic improvement. After 5 months of treatment,
his MRI demonstrated progression of the nonenhancing
tumor and the patient declined clinically. At progression,
he was started on dexamethasone, temozolomide, and
TTFields. NovoTAL mapping was performed targeting
the new nonenhancing FLAIR abnormality (Fig. 3).
Case D
A 55-year-old man developed progressively worsening
headaches, nausea, and vomiting. Imaging revealed a
large right temporal-parietal mass. A biopsy was per-
formed, confirming a GBM, IDH wild-type, MGMT
unmethylated. After 4 cycles of temozolomide, he devel-
oped a visual field deficit, more disorientation, right–left
confusion and difficulty with memory. He was treated
with conventional chemo-RT followed by 4 cycles of ad-
juvant temozolomide. An MRI then revealed new local
growth of mass, as well as the development of a small
new enhancing lesion in the splenium of his corpus cal-
losum. There was significant T2 hyperintensity in this
area consistent with infiltrative disease. Due to this sig-
nificant nonenhancing disease, NovoTAL mapping was
performed incorporating the region of T2 signal change
(Fig. 4).
Case E
A 51-year-old man developed headaches and subse-
quently had a seizure. Imaging revealed an area of ab-
normal T2 hyperintensity in the left insular region. He
underwent a biopsy, which was nondiagnostic. Four
months later, repeat imaging demonstrated an interval
expansion of abnormal T2 hyperintensity. A second bi-
opsy was performed, confirming an anaplastic astrocy-
toma, IDH1 wild-type. He was treated with conventional
chemo-RT followed by 7 cycles of adjuvant temozolo-
mide. Imaging subsequently revealed a new area of ab-
normal enhancement in the medial left temporal lobe.
He elected to initiate treatment with dose-intense temo-
zolomide and concurrent TTFields therapy. NovoTAL
mapping was performed utilizing the extent of the T2
hyperintense signal, rather than focusing solely on the
small area of abnormal enhancement (Fig. 5).
Case F
A 49-year-old woman developed worsening headaches,
dizziness, and falls. Imaging revealed an area of diffuse
abnormal T2 hyperintense signal centered in the right
frontal lobe, extending into the left frontal lobe and deep
right hemisphere. She underwent a stereotactic biopsy of
the right frontal lobe. Pathology revealed an astrocytoma
Fig. 2 a, b & c: Figure a demonstrates parenchymal enhancement in a Gliadel-treated region (shown by the arrow), and an adjacent subdural
collection along the right falx in the T1 postcontrast sequence. Figure b demonstrates an enhancing nodule in the right periventricular region
which correlated to new neurological symptoms. Axial tumor location measurements were performed targeting the TTFields to this specific lesion.
Standard measurements were performed from a reference frame drawn at the outer margin of the scalp. Figure c represents the coronal slice selected
for TTFields treatment planning. A reference frame is drawn at the level of the scalp, extending inferiorly to the lower margin of frontal lobe. At the
clinician’s discretion, tumor location coordinates are determined for the area thought to represent active tumor (arrow)
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grade II, IDH-1 mutated. She opted for treatment with
conventional temozolomide cycles, and concurrent
TTFields therapy. NovoTAL mapping was performed
utilizing the entire area of abnormal T2 signal in the
right frontal lobe as the mass lesion (Fig. 6).
Clinical commentary
Malignant gliomas are often composed of a heteroge-
neously enhancing mass and an infiltrative nonenhan-
cing FLAIR abnormality. This FLAIR abnormality needs
to be distinguished from peritumoral edema and/or
treatment effect. According to the RANO Criteria,
FLAIR changes are incorporated in the tumor measure-
ments with the recognition that these often represent
nonenhancing infiltrative and progressive tumor [14]. It
is at the discretion of the treating physician to determine
which areas most likely represent infiltrative tumor and
should be the target of the TTFields.
Case C represents a common radiographic pattern
seen in glioblastoma bevacizumab failure, characterized
Fig. 4 a, b & c demonstrate treatment planning for a recurrent glioblastoma patient with diffuse infiltrating disease. Figure a shows the T1 with
contrast axial slice demonstrating enhancing tumor. Figure b demonstrates more diffuse FLAIR signal abnormality, including within the
contralateral lobe. As such, treatment is planned using the FLAIR sequence. Standard measurements were performed from a reference frame
drawn at the outer margin of the scalp. Tumor location coordinates are obtained on the axial slice measuring from the right frame to the
proximal and distal extents of FLAIR abnormality. In the absence of a coronal FLAIR sequence, coronal treatment planning is performed using the
T1 postcontrast sequence (figure c). In this slice, the inferior margin of the reference frame is drawn to the lowest visible level of tentorium
Fig. 3 a, b & c: Figure a demonstrates lack of enhancing disease on an axial T1 postcontrast scan in a glioblastoma patient experiencing disease
progression following 5 months of treatment with bevacizumab. Figures b shows the corresponding slice on the axial FLAIR sequence
demonstrating significant FLAIR signal abnormality. As such, TTFields planning was performed on the FLAIR sequence. Measurements were
obtained from a reference frame drawn at the level of the scalp in a standard manner, and measuring from the right frame to the near and far
borders of the FLAIR signal abnormality. Figure c depicts mapping performed in the coronal plane to a corresponding area of hypodensity on
the T1 postcontrast sequence. All measurements are obtained from a reference frame drawn at the level of the scalp, extending inferiorly to the
lower margin of temporal lobe
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by lack of contrast enhancement and progression of ab-
normal T2 signal or FLAIR. The treating physician used
the new area of FLAIR as the target of the TTFields.
Case D represents a scenario where the treating phys-
ician used abnormal T2 signal on the FLAIR series to
delineate the tumor boundary. As the bulk of the tumor
did not enhance with contrast, abnormal FLAIR hyper-
intensity was used to delineate the tumor boundary.
The natural history of grade II and III gliomas is such
that, overtime (months to years), they can often trans-
form to a malignant phenotype. The management of an-
aplastic astrocytomas remains controversial, but most
clinicians opt to treat patients with the same regimen
used to treat glioblastoma; adjuvant chemo radiation
followed by maintenance temozolomide. Although
TTFields have not been prospectively tested in random-
ized controlled trials in low grade gliomas and are not
FDA approved in this setting, they have been used off-
label to treat these patients when other options have
been exhausted, given the highly limited treatment op-
tions available for this population. Radiographically, low-
grade gliomas tend to be nonenhancing and manifest
with abnormal T2 signal or FLAIR. In these scenarios,
as in Case E and F, axial and coronal FLAIR imaging
was used for mapping. If coronal T2 or FLAIR are un-
available, the coronal T1-weighted imaging can be used,
in which case the tumor often appears hypodense. In
Case E, a diffuse astrocytoma, there was no contrast
Fig. 5 a, b & c show a largely noncontrast enhancing tumor. Head size measurements are performed on the FLAIR sequence. The axial
coordinates for head size are shown in figure a. NovoTAL mapping was performed exclusively using figure b axial and figure c coronal FLAIR
images. In the axial view figure b, a reference frame is drawn on the slice demonstrating the greatest extent of FLAIR abnormality. Tumor
coordinates are obtained from the right frame to the near and far edges of FLAIR abnormality at the discretion of the treating physician. In figure
c, coronal tumor location coordinates are obtained from a reference frame drawn at the level of the scalp which extends inferiorly to the lowest
margin of temporal lobe. Distances to the tumor margin are drawn at the discretion of the treating physician to include all the region that is
thought to contain active tumor
Fig. 6 a, b & c demonstrate treatment planning in a patient with exclusively nonmeasurable disease: Figure a is the axial T1 post-contrast slice
demonstrating no contrast enhancement. Figure b is the corresponding axial FLAIR sequence was used to map the tumor coordinates. A
reference frame is drawn around the level of the scalp and tumor location coordinates are obtained from the right framebased on the
extent of abnormal T2 signal. Figure c depicts the coronal treatment planning utilizing the T1 post-contrast sequence. The area of FLAIR
signal abnormality corresponds with an area of T1 hypointensity on the coronal sequence. Treatment is planned to the boundaries of the
T1 hypointensity at the treating physician’s discretion. Tumor location coordinates are obtained in a standard fashion from a reference
drawn at the level of the scalp. The reference frame encompasses all of the supratentorial brain so the lower boundary is extended to
the inferior margin of temporal lobe in this slice
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enhancement seen on MRI. Axial FLAIR images, dem-
onstrating T2 hyperintensity in affected areas of the
brain, were used to obtain mapping coordinates. No cor-
onal T2 or FLAIR sequence was available, so the coronal
T1-weighted image was used to estimate the central area
of the tumor. There was some evidence of T1 hypoin-
tensity, corresponding to T2 hyperintensity.
In Case F, there was no abnormal contrast enhancement
seen on MRI, so the axial T2- and T1-post, as well as the
coronal T1-post were used for NovoTAL mapping. The
mass was T1 hypointense and T2 hyperintense to normal
brain, allowing for drawing of the coordinates up to the
signal change. The cases outlined above demonstrate how
treating physicians can appropriately incorporate none-
nhancing disease into TTFields treatment plans.
Practice scenario 3: incorporating perfusion/diffusion
imaging in treatment planning
Case G
A 65-year-old woman developed progressively worsening
cognitive and speech impairments. Imaging revealed a
large, heterogeneously enhancing left frontal mass ex-
tending to the corpus callosum. She underwent a sub-
total resection, with pathology confirming a GBM,
MGMT methylated, and EGFRvIII positive. She was
treated with conventional chemo-RT and adjuvant temo-
zolomide along with an investigational agent through a
clinical trial. After her second recurrence while on beva-
cizumab, MRI demonstrated an enlarging abnormal T2
hyperintense area. This region also had significant in-
crease in blood flow on MR perfusion (Fig. 5), suggesting
active tumor growth. She opted for continuation of bev-
acizumab and the addition of lomustine and TTFields.
NovoTAL mapping was performed utilizing the new
nonenhancing T2 signal abnormality that had developed
with hyperperfusion. A coronal FLAIR image was un-
available, so an area of hypodensity on coronal T1 with
contrast was also used in mapping (Fig. 7).
Case H
A 49-year-old woman developed progressively worsening
speech impairment. Imaging revealed a nodular area of
Fig. 7 a, b, c & d. Figures a-d depict treatment planning in a recurrent glioblastoma patient presenting with an area of increased perfusion on
sequential imaging. Figure a shows lack of enhancement on the axial T1 postcontrast sequence. Figure b shows axial treatment planning
performed on the corresponding slice in the FLAIR sequence, where diffuse signal abnormality is present. Measurements are obtained from a
reference frame drawn at the level of the scalp. Tumor coordinates are determined in a standard manner correlating the region of FLAIR signal
abnormality with the area of increased perfusion observed on MR perfusion (figure d). Figure c shows the corresponding area of hypodensity on
the coronal T1 with contrast sequence which is used for treatment planning in the absence of a coronal FLAIR sequence. All measurements are
obtained from a reference frame drawn at the level of scalp, extending inferiorly to the lowest margin of frontal lobe. In anterior coronal sections,
the reference frame should encompass all of the cerebrum at this level. Tumor location measurements are obtained in a standard fashion
extending from the right frame to the edges of the T1 hypo intensity. Figure d shows an area of increased perfusion (white arrow) in the left
frontal lobe on MR perfusion indicative of tumor recurrence
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DWI-hyperintense signal (restricted diffusion) in the
deep left frontal lobe. She underwent a stereotactic bi-
opsy confirming an anaplastic astrocytoma, IDH1 wild-
type, and MGMT unmethlyated. She was treated with
conventional chemo-RT. During the fourth week of radi-
ation, she experienced worsening neurological symp-
toms, complete expressive aphasia, and right-sided
hemiplegia. She was started on concurrent bevacizumab
and was able to complete her course of chemo-RT
thereafter continuing on bevacizumab. After 11 months
of therapy, she developed new speech impairment. MRI
demonstrated a new nodule of hyperintense DWI signal
in the high-left frontal lobe, consistent with disease pro-
gression. It was recommended that TTFields be added
as adjunctive therapy. NovoTAL mapping was per-
formed utilizing the DWI sequence, which was corre-
lated to the axial and coronal T1-postcontrast series
(Fig. 8).
Clinical commentary
In some cases, aggressive tumor growth can be better vi-
sualized on MR-perfusion and DWI sequences. MR-
perfusion represents increased blood flow to actively
growing tumor, whereas DWI-hyperintensity represents
a hypercellular environment. This is particularly useful
in the era of antiangiogenic therapies, in which patients
often have little or no contrast enhancement on MRI at
the time of tumor progression. Utilization of these ad-
vanced MR modalities can guide the target of the
TTFields to the area of most active tumor. In Case G,
the area of increased activity on MR-perfusion narrowed
the region of interest on FLAIR. In Case H, the hyperin-
tense DWI signal, which correlated with the patient’s
symptoms, defined the target on T1-postcontrast. In
both cases, the treating physician used advanced MRI
techniques to help target the TTFields.
Discussion
The NovoTAL System is an algorithmic software pro-
gram that creates optimal transducer array layouts based
on patient head size and tumor location measurements
obtained from an MRI [11]. Electric field distribution
within the brain is nonuniform, and is a function of the
direction of a field, individual dielectric properties of adja-
cent tissue structures, and the orientation of the interfaces
between them [9, 10]. The algorithm will compute the op-
timal paired configuration of transducer arrays that should
be applied directly to a patient’s shaved scalp that will lo-
cally deliver the highest intensity of TTFields at the site of
a tumor. The NovoTAL System was FDA approved in
2013 on the basis of a user study that included a total of
14 neuro-oncologists, neurosurgeons, and medical oncol-
ogists who were trained on treatment planning and then
had to independently generate treatment maps for 5
blinded GBM cases [11]. The concordance between phys-
ician mapping and gold-standard in-house mapping per-
formed by the manufacturer’s clinical team was excellent,
with an R2-correlation coefficient for 20 individual meas-
uring parameters exceeding 0.99. Clinicians managing pa-
tients with GBM can choose to become certified in
treatment planning with NovoTAL and there are potential
clinical benefits in their doing so. Unlike NovoTAL map-
ping performed by manufacturer, which exclusively uti-
lizes postcontrast MRI sequences, a treating physician has
access to a patient’s sequential imaging and has compre-
hensive knowledge of a patient’s treatment history. This
can provide a better understanding of subtle changes in
imaging that may or may not represent active disease. In
addition, they have the discretion to integrate other MRI
Fig. 8 a, b & c depict treatment planning in a patient with recurrent anaplastic astrocytoma incorporating DWI sequences. Figure a shows an
axial T1 postcontrast slice demonstrating punctate enhancement. Head size measurements were performed in a standard manner on T1
sequences (not shown). Figure b shows the axial DWI sequence with a clear area of hyperintense signal in the region of active disease which was
used to obtain axial tumor location measurements. A reference frame is approximated around the head at the level of the scalp. Tumor location
coordinates are measured from the right frame to the edges of the DWI signal abnormality thought to represent active tumor at the discretion of
the treating physician. Figure 8c shows the coronal T1 postcontrast slice used to map tumor coordinates in the coronal plane. Treatment was
planned measuring from a reference frame drawn at the level of the scalp extending to the lowest margin of visible tentorium. Tumor location
coordinates are measured from the right frame to the edges of faint enhancement and gyral thickening
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or advanced imaging sequences into the planning process,
which may better reflect the true extent of active disease
(such as T2, FLAIR, diffusion weighted imaging, or MR
perfusion), or rely on these sequences at their discretion
in instances when postcontrast sequences are missing. In
addition, should a patient’s imaging change significantly
from baseline while on TTFields, the managing physician
can decide whether re-mapping the treatment field is
warranted [15].
Conclusion
Glioblastomas can have a diverse appearance within
MRI images. In general, they appear as an enhancing le-
sion(s) on T1 post-contrast imaging. However, after
treatment, not all contrast enhancement represents
tumor and may actually depict treatment effect such as
pseudoprogression. This needs to be taken into consid-
eration by the treating physician, as shown by several of
the cases above. Also, as demonstrated in the cases
above, there are often circumstances where the active
tumor is non-enhancing, and can only be visualized on
FLAIR, MR-perfusion, or diffusion sequences. The lack
of contrast-enhancing disease seen on MRI should cer-
tainly not preclude patients from receiving TTFields
therapy. Future prospective studies may seek to under-
stand not only the response rates of nonenhancing and
other MRI sequences of glioblastoma treated with
TTFields therapy, but also their correlation with mo-
lecular alterations in this tumor.
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